Register       Forgot Password?

 
Advanced Search
Home About Us Downloads Products Support Job Opportunities Terms & Conditions Contact Us Shopping Cart (0)
TRC News
1) FDA approved BTG's Voraxaze® (glucarpidase) for the treatment of toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function. Clearance in the U.S. was granted under priority review, and was based on data from 290 patients treated in two open-label multicenter studies. BTG saysVoraxase is the first product BTG has taken through to approval in the U.S. Link...
Subscribe to Newsletter
TRC
Newest Chemicals
A104990 A105000 A105002 A108500 A108500
A104990 A105000 A105002 A108500 A101000
JME Molecular Search Engine JME Molecular Search Engine JME Molecular Search Engine